Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051714 | 0.87 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL2193248 | 0.80 | HCRTR1 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL934131 | 0.80 | HCRTR1 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL6126614 | 0.77 | HCRTR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL14979634 | 0.75 | PTGES (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL22361254 | 0.73 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL18813763 | 0.71 | LIPG (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL18813762 | 0.71 | LIPG (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL1908293 | 0.71 | LIPG (0.35) | — | |
| SCHEMBL1908290 | 0.71 | LIPG (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8921341-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885 |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885 |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.